R&D | December 05, 2025
DBT, BIRAC and CEPI renew cooperation agreement for vaccine development
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
Angelini Ventures has already invested €125 million in 22 startups
Presbyopia, the age-related loss of near vision, could soon be treated successfully
Most recently, Yuvraj was the Director of Operations, Business Development & Process Excellence at Zeon Lifesciences Ltd
The clearance for TELLTALE positions Transmural Systems at the forefront of next-generation electrosurgical solutions for structural heart interventions
The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
These certifications reflect the company's continuous commitment to maintaining international standards of environmental sustainability as well as occupational health and safety
Subscribe To Our Newsletter & Stay Updated
